Rafael (RFL)
Develops Trappsol Cyclo while holding healthcare, infusion-technology, and real-estate interests.
Something off on this page? Send us feedback.
Develops Trappsol Cyclo for Niemann-Pick disease type C, its lead clinical asset. The holding company also owns interests spanning healthcare, Day Three's Unlokt infusion technology, and a commercial real-estate property in Israel.
Develops Trappsol Cyclo, a clinical candidate for Niemann-Pick disease type C that became the lead asset after the Cyclo Therapeutics combination. The healthcare portfolio also includes majority interests in LipoMedix, Barer, Cornerstone, and Rafael Medical Devices.
The Infusion Technology segment holds a majority interest in Day Three and earns revenue from its Unlokt technology. Real Estate consists of a portion of one commercial building in Israel. Together, those operations retain the company's holding-company structure alongside its clinical program.
Howard S. Jonas controls shareholder voting power. The clinical trajectory depends on TransportNPC topline data and subsequent regulatory progress.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $30.5M · Total debt $610.0K · Total assets $92.0M · Shareholders' equity $75.4M
- Revenue
- $179.0K
- Operating income
- −$6.9M
- Net income
- −$4.2M
No dividends on record.
| Institutions | 7.49% | 3.89M shares | |
|---|---|---|---|
| 44 holders · as of Jun 30, 2026 | |||
| Insiders | 31.67% | 16.47M shares | |
| 11 holders · as of Jun 23, 2026 | |||
| Strategic holders | 6.95% | 3.62M shares | |
| 1 holder · as of Jun 9, 2025 | |||
| Other | 53.89% | 28.02M shares | |
| remainder | |||
52.00M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Howard S. Jonas1Insiderdirector, 10 percent owner, officer: Exec Chairman, CEO & President | 28.25% | 13.59M B · 787,163 A · 100 | filed Jun 9, 2025 |
i9 PLUS, LLCStrategicdirector | 6.95% | 3.62M B | filed Jun 9, 2025 |
Vanguard Capital Management LLCInstitution | 2.63% | 1.37M B | as of Jun 30, 2026 |
William ConklingInsiderofficer: Chief Executive Officer | 1.09% | 564,455 B | filed Apr 24, 2025 |
Geode Capital Management, LLCInstitution | 0.83% | 429,879 B | as of Jun 30, 2026 |
- The filed share classes (B, A, COMMON) could not be matched to the company's, so no percentage.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Zevra Therapeutics
Approved NPC therapy MIPLYFFA, used with miglustat
- Johnson & Johnson
EU-authorised Zavesca for NPC neurological manifestations
- Stryker
Orthopaedic technologies overlapping minimally invasive instruments
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rafael | $2.06 | +3.00% | $102.4M | — | — | 104.5 | −50.6% |
| Zevra Therapeutics | $11.70 | +0.25% | $689.9M | 12.5 | 14.0 | 5.1 | +53.3% |
| Johnson & Johnson | $268.61 | −0.32% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Stryker | $276.15 | +0.71% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Median | 28.4 | 17.2 | 5.1 | +9.4% |